GRAIL surges as FDA briefing doc shows positive evaluation of Galleri cancer test
GRAL shares are surging after a positive assessment of Galleri, a cancer diagnostic test, was confirmed in the FDA’s briefing document.
We considered buying after confirming a sharp upward move accompanied by strong trading volume, along with the significant positive catalyst of the FDA briefing document’s favorable assessment. The current stock price is above the indicated resistance and support levels.
If the stock price continues its upward trend and reaches the resistance level of $85.49, we will take partial profits. If it moves downward and falls below the support level of $73.46, we will sell in accordance with our stop-loss policy.
RSI(14) is at a neutral level of 52.8, neither overbought nor oversold, and the moving averages show a bullish alignment. Trading volume has increased 3.91x compared with the 20-day average, while the recent 7-day volatility stands at +4.2%.
Driven by the clear positive catalyst of the FDA panel's favorable assessment, and accompanied by heavy trading volume reaching 3.91 times the 20-day average, the actual return significantly outperformed the predicted return of 4.5%, recording 16.1%. With the moving averages in a bullish alignment (stacked in ascending order), a surge unfolded above both resistance and support levels. Consequently, market buying pressure concentrated much more strongly than anticipated, reaching an OVERHIT judgment.
As confirmed in this trade, during periods accompanied by clear regulatory catalysts and surging trading volume, we will apply a flexible profit-taking strategy to our next trade that leaves room for further momentum expansion beyond the initial target price.